Find any stock by ticker or company name
NGM – Real Time Price. Currency in USD
7.40
-0.29 (-3.77%)
At close: Jun 26, 2026, 4:00 PM EDT
7.40
0.00 (0.00%)
After-hours: Jun 26, 2026, 4:10 PM EDT
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models. It is also involved in the development of BBO-10203, an orally bioavailable small molecule, which is in Phase I clinical trial for the treatment of patients with HER2+ breast cancer, HR+/HER2- breast cancer, KRAS mutant colorectal cancer, and KRAS mutant non-small cell lung cancer; and precision oncology assets for patients with tumors. The company was incorporated in 2016 is headquartered in South San Francisco, California.
| Name | Position |
|---|---|
| Dr. Frank P. McCormick Ph.D. | Co-Founder, Non-Executive Director & Chair of the Advisory Board |
| Dr. Neil Kumar Ph.D. | Executive Chairman |
| Dr. Pedro J. Beltran M.D., Ph.D. | Chief Executive Officer and Director |
| Dr. Yong Ben M.B.A., M.D. | Chief Medical & Development Officer |
| Mr. Aaron Chan J.D. | Vice President of Legal |
| Mr. Bin Wang Ph.D. | Senior Vice President of Drug Discovery |
| Mr. Daniel Watson Ph.D. | Senior Vice President of Chemistry, Manufacturing & Controls |
| Mr. Idan Elmelech M.A., M.B.A. | Chief Operating Officer |
| Mr. Marc Cobo | VP of Finance & Controller |
| Mr. Rui Xu Ph.D. | Senior Vice President of Drug Discovery |
| Date | Type | Document |
|---|---|---|
| 2026-05-12 | 8-K | bbot-20260512.htm |
| 2026-05-12 | 10-Q | bbot-20260331.htm |
| 2026-04-30 | POS AM | d480864dposam.htm |
| 2026-04-28 | DEFA14A | d95309ddefa14a.htm |
| 2026-04-28 | DEF 14A | d133143ddef14a.htm |
| 2026-04-28 | ARS | d134712dars.pdf |
| 2026-04-23 | 8-K | d253464d8k.htm |
| 2026-03-26 | 8-K | d126641d8k.htm |
| 2026-03-05 | 8-K | bbot-20260305.htm |
| 2026-03-05 | 10-K | bbot-20251231.htm |